Results 191 to 200 of about 171,246 (253)

The translation factor eIF4E is a key mediator of doxorubicin resistance: insights from a triple-negative breast cancer model. [PDF]

open access: yesSci Rep
Frayde-Gómez H   +10 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Doxorubicin Nanoconjugates

Journal of Nanoscience and Nanotechnology, 2014
Doxorubicin is one of the most widely administered drugs for treatment of cancer. The shortcomings commonly encountered with this drug are severe cardiotoxicity, narrow therapeutic indices, and the development of multiple drug resistance. Hence, several nanoparticulate drug delivery systems have been designed to overcome these limitations and to ...
Kannan, Deepa   +2 more
openaire   +2 more sources

Liposomal Doxorubicin

Journal of Drug Targeting, 1996
Doxorubicin is a potent antineoplastic agent with activity against numerous human cancers. Encapsulation of doxorubicin inside a liposome alters bioavailability, biodistribution and thus its biological activity significantly. The physical properties of the liposome (size, lipid components and lipid dose) play a major role in determining drug retention ...
P G, Tardi, N L, Boman, P R, Cullis
openaire   +2 more sources

Doxorubicin (z.B. Doxorubicin „Ebewe“, Adriblastin®)

2006
aufgrund zahlreicher Berichte uber Nekrosen erfolgt die Einstufung von Doxorubicin als ...
openaire   +1 more source

Home - About - Disclaimer - Privacy